Seblewongel Asrat
- Immunology and Allergy top 5%
- Endocrinology top 5%
- Legionella and Acanthamoeba research 3
- Dermatology top 5%
- Otorhinolaryngology top 5%
- Immunology top 10%
- IL-33, ST2, and ILC Pathways 8
- Immune Cell Function and Interaction 4
- Mast cells and histamine 2
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms 2
- T-cell and B-cell Immunology 2
-
- Asthma and respiratory diseases 7
-
- Eosinophilic Esophagitis 5
Seblewongel Asrat
17 papers receiving 668 citations
Hit Papers
Peers
Comparison fields: 5 of 73
- Immunology and Allergy 197
- Endocrinology 121
- Dermatology 116
- Otorhinolaryngology 53
- Immunology 237
Countries citing papers authored by Seblewongel Asrat
This map shows the geographic impact of Seblewongel Asrat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seblewongel Asrat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seblewongel Asrat more than expected).
Fields of papers citing papers by Seblewongel Asrat
This network shows the impact of papers produced by Seblewongel Asrat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seblewongel Asrat. The network helps show where Seblewongel Asrat may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Seblewongel Asrat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2024 | 6 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 0 | |
| 5 | 2023 | 7 | |
| 6 | 2023 | 0 | |
| 7 | 2022 | 3 | |
| 8 | 2022 | 54 | |
| 9 | 2022 | 1 | |
| 10 | 2020 | 60 | |
| 11 | 2020 | 5 | |
| 12 | Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammationbreakdown → | 2019 | 330 |
| 13 | 2019 | 2 | |
| 14 | 2019 | 5 | |
| 15 | 2019 | 1 | |
| 16 | 2015 | 41 | |
| 17 | 2014 | 50 | |
| 18 | 2014 | 105 | |
| 19 | 2011 | 5 |
About Seblewongel Asrat
Seblewongel Asrat is a scholar working on Endocrinology, Immunology and Immunology and Allergy, having authored 19 papers that have together received 679 indexed citations. Recurring topics across this work include IL-33, ST2, and ILC Pathways (8 papers), Asthma and respiratory diseases (7 papers), Eosinophilic Esophagitis (5 papers), Immune Cell Function and Interaction (4 papers), Legionella and Acanthamoeba research (3 papers), Mast cells and histamine (2 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (2 papers) and T-cell and B-cell Immunology (2 papers). The work is most often cited by research in Immunology and Allergy (197 citations), Endocrinology (121 citations) and Dermatology (116 citations). Seblewongel Asrat has collaborated with scholars based in United States and France. Frequent co-authors include Ralph R. Isberg, Jamie Orengo, Andrew Murphy, Matthew A. Sleeman, Jeanne Allinne, Wei Keat Lim, George Scott, Audrey Le Floc’h, Kirsten Nagashima and Dylan Birchard. Their work appears in journals such as Diabetes, Journal of Allergy and Clinical Immunology and Infection and Immunity.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.